State Street's slightly increased passive stake is routine for a large index/asset manager. No change in investment thesis. Monitor for any future 13D conversion or material changes in ownership by active managers like Point72, which also filed a 13G/A in May 2026.
CRVS drugs
CRVS drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+1- T+0 · Nov 10 $11.37entry
- T+1 · 6d ago +0.88%α −0.44% · $11.47
- T+4 · todayOpen
- T+5 · in 4h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
How similar events traded
Executive Summary
State Street Corp filed a Schedule 13G disclosing a passive 5%+ stake in Corvus Pharmaceuticals as of September 30, 2026. This is an amendment to State Street's prior 13G filed August 7, 2026, showing a slight increase in share count from 3,233,973 to 3,331,535 shares. The filing confirms continued passive institutional ownership with no activist intent.
Key Financial Metrics
Key Facts
- State Street Corp filed Schedule 13G for Corvus Pharmaceuticals as of September 30, 2026
- State Street beneficially owns 3,331,535 shares of common stock
- This is an amendment to State Street's prior 13G filed August 7, 2026, which reported 3,233,973 shares
- The filing certifies passive investment intent under Rule 13d-1(b)
- State Street is a large custodial bank and asset manager, not an activist investor
Financial Impact
State Street holds 3,331,535 shares; stake value approximately $107M based on market cap of $889M and top holder data showing BlackRock at $107M
Risk Factors
- No material risks identified from this routine passive filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| SC 13G Filing (Primary) | 0000093751-26-000636 |
| Document: 0000093751-26-000636-index.html | 0000093751-26-000636 |
| Document: 0000093751-26-000636.txt | 0000093751-26-000636 |
Track record
15 reports on CRVS
1 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +2.61% at T+1 after the Mar 12, 2026 report. 2 of 3 went positive at some point.
Filters
- Nov 13, 20263d ago Insider Buy Neutral 3/10 Entry $11.20 Now $10.60 −5.36% settles Feb 12
- Nov 10, 20266d ago SC 13G Neutral 3/10 Viewing Entry $11.37 Now $10.60 −6.77% settles Feb 8
- Nov 5, 202611d ago 8-K Neutral 4/10 Entry $10.54 Now $10.60 +0.57% settles Feb 4
- Nov 5, 202611d ago Press Release Neutral 4/10 No price data
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $10.57 Now $10.60 +0.28% settles Feb 2
- Sep 30, 20266w ago Press Release Neutral 3/10 Entry $10.93 Now $10.60 −3.02% settles Dec 28
- Aug 21, 202612w ago Institutional Cluster Bullish 6/10 Entry $14.46 to $10.60 Now $10.60 −26.69% ▼ −26.69% −23.33% vs SPY
- Jul 22, 202616w ago 8-K Neutral 2/10 Entry $13.68 to $9.85 Now $10.60 −22.51% ▼ −28.00% −32.55% vs SPY
- Jun 11, 202622w ago Institutional Cluster Neutral 3/10 Entry $11.60 to $14.39 Now $10.60 −8.62% ▲ +24.05% +19.66% vs SPY
- May 14, 202626w ago 8-K Bullish 7/10 Entry $13.66 to $13.74 Now $10.60 −22.37% ▲ +0.62% −2.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers